This round is no longer accepting investments, but hundreds just like it are live now.

Log In

INVEST IN 20/20 GENESYSTEMS, INC. TODAY!

Cutting Edge Diagnostic Testing for COVID-19 & Cancer

20/20 GeneSystems (“20/20”) is a digital diagnostics company with a core mission of reducing cancer mortality through early detection. we expanded our test menu to include an array of Covid-19 testing solutions. Year-over-year revenues have increased by over 300%

This Reg A+ offering is made available through StartEngine Primary, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$1,510,607.20 Raised

Offering Circular |Supplement 1 |Supplement 2 |Supplement 3 | Selected Risks Related to this Offering
20/20 GeneSystems' SEC EDGAR Page"Signed to Trade" disclosure

For more information on 20/20 GeneSystems Inc. download and review the Offering Circular. The Offering Circular should be reviewed before making an investment decision


20/20 GeneSystems has also raised $2,238,112.80 towards the offering maximum for this offering outside the platform through another broker-dealer.


Reasons to invest



  • Huge Market - The global cancer diagnostics market was valued at $7.1 billion in 2015 and is projected to reach $13.1 billion by the year 2020
  • Experienced Team - Our CEO previously established strategic partnerships with Fortune 500 companies such as Johnson & Johnson, Eastman Kodak, Abbott Diagnostics and Smiths Detection
  • Traction - We're backed by China’s Ping An Ventures, likely the world’s largest Healthcare AI company (300 million users of its mobile diagnostic app) & thousands of investors


Contributing to the Fight Against Cancer & COVID-19 with “Digital Diagnostics”


20/20 is pioneering a brand new approach to improve the accuracy and usefulness of conventional clinical lab testing. Rather than simply reporting the biomarker levels, in the way they have for decades, we leverage vast amounts of real-world data together with machine learning to compare the individual’s test results to those of tens of thousands of others with known health outcomes. This proprietary technique is already being used to improve early cancer detection and will soon be deployed to monitor the immunity protection after vaccination.  Plans are in the works to expand to heart disease and other chronic conditions. 



For more information about the rapid test, visit our website at www.CoronaCheckTest.com.



Our story


Early Detection of Cancer

Cancer is the 2nd leading cause of death in most of the industrialized world with survival rates closely tied to stage at time of diagnosis. For example, the 5-year survival rate for lung cancer falls 90% when it passes from Stage 1 to Stage 4.



We believe 20/20 is positioned to help transform the way cancer is screened worldwide, and in doing so, help score a major victory in the fight against this dreaded disease. Despite advancements in treatment, once cancer has gone undetected through its early stages, it frequently becomes lethal. Therefore, the key to winning the fight against cancer is transforming the way cancer is screened for and detected.    


the solution


20/20’s OneTest: A machine learning enhanced blood test to help detect multiple cancers early


OneTest™ aids in the early detection of multiple cancers from one blood sample. See www.OneTest.AI. In the U.S., the product includes a laboratory developed blood test comprising 6 biomarkers and a machine learning algorithm. Customers have their blood draws sent to our CLIA lab where we perform our analysis and then report the results. Overseas we provide the algorithm only as the biomarker testing can be conducted at thousands of laboratories around the world. This approach is capital efficient and protects our IP.


Testing of tumor markers is performed at the 20/20 GeneSystems’ CLIA laboratory using the Roche Cobas e411 platform. FDA approved Roche IVD reagent kits are used according to manufacturer specifications. Results of individual tumor marker tests are used to calculate a risk score using a proprietary machine-learning algorithm and then generate a patient report. The OneTest report provides the following information to the patient:


  1. The individual biomarker levels  
  2. An overall cancer risk OneTest Score calculated using a machine learning algorithm


OneTest International Market Process



Key features of the current product are as follows:

  • A cloud accessible tool to improve the accuracy of tumor marker blood tests (CEA, AFP, CA-19.9, etc.)
  • Useful in early detection of multiple types of cancer (lung, liver, pancreas, etc.)
  • Incorporates clinical factors (age, gender, smoking history, etc.)
  • Stores & displays each individual’s biomarker trends from successive tests
  • Uses machine learning / AI

The technical underpinnings of OneTest™ are described in a high impact, reputable peer-reviewed journal article: Wang, et al. “Improving Multi-Tumor Biomarker Health Check-Up Tests with Machine Learning Algorithms”. Cancers 2020, 12, 1442 that was published June 1, 2020.  


To the best of our knowledge, 20/20 is the first company to commercialize multi-cancer screening blood tests powered by AI and machine learning algorithms built with real-world outcome data from tens of thousands of previously tested individuals. Screening tests and algorithms must be validated in a “pre-diagnostic” population (i.e. individuals tested before being diagnosed with cancer) to be proven reliable. Our approach of “harvesting” real-world data permits rapid validation from this population with limited costs.


These proprietary algorithms combine the levels of multiple tumor biomarkers (such as CEA, AFP, CA-125, etc.) with clinical factors (e.g. age, gender, smoking history, etc.) and automatically finds “look-alikes” between the tested individuals and tens of thousands of individuals previously tested with the same biomarkers for whom cancer incidences are known.


Biomarker trends from repeat tests are collected, displayed, and stored on our portal since rising biomarker levels often signal an early-stage disease.


In the U.S. we sell OneTest (www.OneTest.AI) to both individuals and occupational groups (e.g. Fire Departments) with proven high cancer risk. Overseas we make the OneTest algorithm available on the cloud to health examination centers on a subscription basis.

Market


Who should get OneTest? 

We believe that ultimately everyone, everywhere, should take OneTest every year. Recent studies by leading cancer geneticists at Johns Hopkins suggest that far more cancers are caused by aging than from family history, the environment, or lifestyle. This suggests that all adults, beginning in middle age, should be screened regularly for a wide array of cancers. In fact, throughout East Asia most adults receive tumor antigens testing each year at “Health Check Centers.”


Thus the market for multi-cancer screening blood tests includes all adults worldwide roughly between the ages of 45 and 75 (the optimum ages for cancer screening). Currently, there are no widely used safe and affordable tests that help identify as many cancers as our OneTest at comparable price and accuracy levels.



While we see OneTest being a universal test in the long-term in the near-term we are focusing on occupations with proven high incidents of lethal cancers. Studies by the U.S. National Institute of Occupational Safety & Health (NIOSH) demonstrate that firefighters are one such occupation. Thus, America’s more than one million career and volunteer firefighters are a key market for OneTest. See www.OneTestforCancer.com/firefighters.



To date OneTest has been ordered for over 3,500 firefighters including orders from over 30 separate fire departments in 16 states.  In January the Fairfax County, VA recently ordered the test for nearly 1,500 of their members using a grant from the Federal Emergency Management Agency.  





Covid-19 Testing

About one month into the start of the pandemic we began to source and procure rapid tests backed by strong scientific evidence.  Currently 20/20’s COVID-19 tests include a viral (PCR) test whose customers are nursing homes and County and State governments, rapid antibody tests with pharmacies as customers, antigen tests with customers being a service provider to and operators of clinics, and a Roche quantitative test with independent pharmacies and urgent care facilities as customers.


COVID Antibody Tests


Rapid Antibody Tests - Early in the pandemic we leveraged our relationships in China to procure and validate rapid COVID-19 antibody tests that can be used at clinics and pharmacies. To date we have sold COVID-19 antibody tests generating over $1.2 million in revenues. Our approach in COVID-19 testing has been to affiliate with the best products available (versus developing and manufacturing our own) so as to accelerate our time to a market in a highly fluid environment. This approach also preserves capital while minimizing the risk of being stuck with a technology from which the market moves away.  



Independent pharmacies have been among our most active customers of rapid antibody tests. We believe that this large market segment (there are over 20,000 independent pharmacies in the U.S.) is ripe for growth with additional testing products after the pandemic.


Quantitative Antibody Testing - We also offer one of the first quantitative tests for COVID-19 antibodies that can accomodate capillary blood from a fingerstick, in lieu of venous blood drawn by a phlebotomist. This arrangement permits fingerstick blood specimens to be collected at a pharmacy and sent to 20/20’s CLIA lab for quantitative analysis.


The quantitative test,  purchased by us from Roche Diagnostics, is expected to be useful following vaccination to assess the durability of immunity. Before a vaccine is administered it is important to know the starting level of antibodies a person has, in order to evaluate any change in antibody levels that the vaccine induces, especially the development of antibodies directed against the SARS-CoV-2 spike protein. These antibodies have been shown to have potent antiviral activity and correlate to potential immunity. Monitoring antibody levels over time may become vital in assessing the durability of immunity in the months after vaccination.  


We are in the process of organizing studies with local and international partners to help ascertain the precise antibody levels below which protective immunity begins to wane. Our goal is to develop a machine learning algorithm for Covid immunity monitoring similar to the approach we used for early cancer detection.


Viral (PCR) Testing


In September 20/20 introduced molecular (PCR) testing in our CLIA lab which previously ran only immunoassays for tumor markers.  We began running COVID-19 nasal swab specimens from three Maryland nursing homes. This testing activity is expected to grow at least through the second Quarter of 2021.    


Long-term Value from COVID Testing Experience


In addition to revenue generation, we believe the profits from which will be re-invested in longer term growth opportunities, pandemic testing will create shareholder value after the emergency in at least the following ways:


  • New testing equipment, acquired for Covid-testing can be used in other disease areas. More specifically our CLIA lab, is for the first time able to conduct DNA analysis rather than just proteins and  immunoassays.
  • New market segments and verticals have been established.  In particular we are now selling tests to over 35 independent pharmacies.   We believe that pharmacies could become an accessible venue for our OneTest and future diagnostics in other disease areas.  
  • New test developers have been identified and are currently supplying us with tests for sale in the U.S.  These test developers and manufacturers will likely expand their test menus after “herd immunity” is reached.  20/20 plans to seek co-development and exclusive marketing relationships with some of these developers.

growth


New Customers, Collaborators, Technologies, and Other Resources acquired during the pandemic will help propel our growth in 2021 and beyond!

20/20’s Growth Trajectory - Between 2019 and 2020 our company’s year-over-year revenues grew by 700% largely as a result of pandemic related testing.  According to the Inc. 5000 annual list such growth would put us among the 1000 fastest growing companies in America.



Key goals and priorities to help yield sustained commercial traction and revenue growth in the 24 month period following the pandemic emergency include the following:


  • Significantly Grow OneTest for Cancer in the USA. Improvements that would permit faster scale of this product include the use of capillary blood collected via fingerstick versus venous blood collected by a dedicated phlebotomist. This approach, following significant equivalency studies, would permit OneTest to be offered in pharmacies which do not typically employ phlebotomists.  
  • Develop OneTest for Heart Health. We are in discussions with a leading research institution about a panel of blood based cardiac markers that can be combined with blood pressure and EKG that use machine learning algorithms that can help predict the likelihood of cardiac arrest and stroke.
  • Launch OneTest Algorithm Portal in China and Russia. 20/20 is actively planning new initiatives in both China and Russia for the commercialization of the OneTest portal and algorithm due to the common testing of tumor markers in healthy populations in both of those countries.


leadership



20/20 consists of a very enthusiastic and driven team dedicated to our core mission of reducing cancer mortality in the U.S. and around the world through early detection.  We are focused on trying to save as many lives as possible while also creating a successful and sustainable business.  As you can see in the “Bios” section, 20/20 has assembled a very diverse and experienced team with expertise across various aspects of science and business.





why invest


Invest in saving lives

Thanks to recent legislative changes you can now own shares of a company we believe is uniquely positioned for growth and with the ability to save many thousands of lives around the world (perhaps yours or a loved one).  


faqs


ABOUT OUR CANCER TESTS


Does OneTest require FDA pre-market approval?


No.  As a “laboratory developed test” (LDT) run out of the clinical laboratory that developed it, OneTest is regulated under the Clinical Laboratory Improvement Act (CLIA) by the Center for Medicare & Medicaid Services (CMS) and the Maryland Department of Health.  FDA, with rare exceptions, does not participate in the regulation of  LDTs.  In general, CLIA approval is directed at laboratory procedures and the technical performance and analytical validity of the test (i.e. whether the test delivers consistent results) rather than the impact of the test on disease outcomes.  However the instrumentation and detection kits used in our CLIA lab are FDA cleared.  For example, PSA is approved for screening for prostate cancers. The other biomarker detection kits that we use are approved for assisting in diagnosing cancer, monitoring cancer recurrence, and / or therapeutic monitoring. However, several foreign counterparts to the FDA have approved the biomarker test kits we use for use in screening and early detection resulting in the same tests we are using being employed in those countries for the yearly screening of tens of millions of individuals.



What makes OneTest better than its competitors?


While there are very few multi-cancer screening blood tests on the market, there are many emerging competitors, most utilizing sequencing of circulating tumor  DNA.  Some of OneTest’s key advantages over these competitors are: use of proven biomarkers, vast sets of real-world data,  and affordability.  OneTest’s underlying panel consists of well known markers used to test tens of millions of individuals each year, primarily in East Asia.   Enhancing the power of these markers is our unique access to the real data of over 200,000 real world patients which allows the AI algorithms to extrapolate one’s cancer risk to a higher degree of accuracy.  The DNA sequencing tests are expected to price at around $600 to $1000 versus $189 for OneTest, an important differentiator since all of these tests will be self-pay for the foreseeable future.



Who should be tested with your multi-cancer blood test? 


Most people incorrectly assume that family history, lifestyle, and environmental exposures are the leading causes of cancer. However, a 2017 study by leading cancer geneticists from Johns Hopkins found that among all tumor types, 66% of the genetic mutations that lead to cancer come from random mutations over a lifetime, 29% from lifestyle or environment, and only 5% from genes inherited from parents. Thus, even those who have little or no family history of cancer and who lead a healthy lifestyle would be wise to routinely screen for cancer. This is the standard practice in Japan, Korea, China and throughout the Far East where nearly all adults, starting at about age 40, undertake day-long annual health checks that usually include blood tests of many of the same protein biomarkers that are part of OneTest.



How accurate is your test?


For detailed information on the accuracy of OneTest, please visit our website https://onetestforcancer.com/learn/. Then, click the “Accuracy, Reliability & Scientific Support” tab.



Are your tests covered by health insurance?


The COVID-19 tests we offer are reimbursed by insurance.  But not our cancer tests.  With rare exceptions, health insurance (including Medicare) primarily covers treatments and tests for those that have, or are suspected to have an illness or injury. Very few preventative services and screenings for persons without disease symptoms are covered and the exceptions follow ironclad proof that the benefits of the product outweigh the costs of screening hundreds of thousands of individuals over many years. Thus, even in East Asia and Europe, where blood tests for cancer screenings are far more common than in the U.S., screening tests are usually paid for by employers and the individual consumer, not insurance plans. While we do not expect the major insurance plans to cover OneTest any time soon, most HSA / Flex spending accounts can be used for payment.



ABOUT CORONAVIRUS TESTS


What is the value of Covid-19 antibody tests?


Many experts believe that antibody tests, especially those that quantify the levels of antibodies, will be critical in monitoring the strength and durability of immunity in the months following vaccination.  While the precise antibody levels needed for protective immunity are not yet clear, many groups, including 20/20, are committed to conducting research to help identify those numbers.  



How might the company replace these revenues after everyone is vaccinated?


We expect to sell additional products (e.g. OneTest) to some of our newer customers such as pharmacies.   Additionally royalties for licensing our algorithms overseas, especially in Russia, may compensate for some of the revenues we are now deriving from pandemic related diagnostics.  



Due to circumstances related to COVID-19, 20/20 GeneSystems, Inc. is not able to meet the filing deadline required by Regulation A for its Annual Report on Form 1-K for the year ended December 31, 2019. The Company is relying on the temporary final rules adopted by the Securities and Exchange Commission, which provides a 45-day extension to file the Form 1-K, and intends to file its Form 1-K on or before June 15, 2020.


AN OFFERING STATEMENT REGARDING THIS OFFERING HAS BEEN FILED WITH THE SEC. THE SEC HAS QUALIFIED THAT OFFERING STATEMENT, WHICH ONLY MEANS THAT THE COMPANY MAY MAKE SALES OF THE SECURITIES DESCRIBED BY THE OFFERING STATEMENT. IT DOES NOT MEAN THAT THE SEC HAS APPROVED, PASSED UPON THE MERITS OR PASSED UPON THE ACCURACY OR COMPLETENESS OF THE INFORMATION IN THE OFFERING STATEMENT.


THE OFFERING CIRCULAR THAT IS PART OF THAT OFFERING STATEMENT CAN BE FOUND HERE.


THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY.  THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT.  WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS, WHICH CONSTITUTE FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS.  INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE.  THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.


WHILE THE COMPANY HAS SIGNED A QUOTATION AGREEMENT TO TRADE THE SECURITIES OFFERED ON STARTENGINE SECONDARY’S NEW ALTERNATIVE TRADING SYSTEM (THE “ATS”), A COMPANY WHICH INTENDS TO BE QUOTED ON THE MARKETPLACE WILL BE SUBJECT TO CERTAIN REQUIREMENTS WHICH THE COMPANY MAY OR MAY NOT BE ABLE TO SATISFY IN A TIMELY MANNER. EVEN IF A COMPANY IS QUALIFIED TO QUOTE ITS SECURITIES ON THE MARKET, THERE IS NO GUARANTEE AN ACTIVE TRADING MARKET FOR THE SECURITIES WILL EVER DEVELOP, OR IF DEVELOPED, BE MAINTAINED.  YOU SHOULD ASSUME THAT YOU MAY NOT BE ABLE TO LIQUIDATE YOUR INVESTMENT FOR SOME TIME OR BE ABLE TO PLEDGE THESE SHARES AS COLLATERAL.


Paragraph Format

ABOUT

HEADQUARTERS
251 Little Falls Drive
Wilmington, DE 19808

20/20 GeneSystems (“20/20”) is a digital diagnostics company with a core mission of reducing cancer mortality through early detection. we expanded our test menu to include an array of Covid-19 testing solutions. Year-over-year revenues have increased by over 300%

TEAM

Jonathan Cohen

Jonathan Cohen

Chief Executive Officer and President, Director

Jiming Zhou

Jiming Zhou

Chief Operating Officer

John Compton

John Compton

Chairman of the Board

Richard M. Cohen

Richard M. Cohen

Director

Michael Leibowitz

Michael Leibowitz

Chief Scientific Officer

Michael Ross

Michael Ross

Director

John Rollins

John Rollins

Director

Jayson Lee

Jayson Lee

Diretor

Anne Shiflett

Anne Shiflett

Director of Finance

Amy Colton

Amy Colton

Senior Sales Representative

TERMS

20/20 GeneSystems, Inc.
Overview
PRICE PER SHARE
$5.77
DEADLINE
Jun 16, 2021
VALUATION
$57.38M
FUNDING GOAL
$10k - $14.7M
Breakdown
MIN INVESTMENT
$501.60
MAX INVESTMENT
$1,999,998
MIN NUMBER OF SHARES OFFERED
1,733
MAX NUMBER OF SHARES OFFERED
2,547,660
OFFERING TYPE
Equity
ASSET TYPE
Preferred Stock
SHARES OFFERED
Series D Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

$2,500+ Investment: For those who invest $2,500, two transferable multi-cancer or lung tests. (Only if available in your country)

$10,000+ Investment: For those who invest $10,000, six transferable multi-cancer or lung tests. (Only if available in your country)

$75,000+ Investment: For those who invest $75,000, twenty transferable multi-cancer or lung tests. (Only if available in your country)

$100,000+ Investment: For those who invest $100,000, a lifetime of annual cancer screenings for a spousal pair. (Only if available in your country)

$200,000+ Investment: For those who invest $200,000, all the above perks plus all-expenses-paid trip (airfare & lodging) for 1 to travel to Taiwan for a 2-day start-of-the-art platinum level medical checkup, including OneTest + full battery of tests for all body systems.

$250,000+ Investment: For those who invest $250,000, all of the above live campaign perks for two individuals.

$500,000+ Investment: For those who invest $500,000, all of the above live campaign perks for four individuals.

ALL UPDATES

06.15.21

FINAL HOURS LEFT!

This is a final warning to all potential investors to not get left behind on this offering!  This has been an incredible journey and we know our investors are some of the best out there.  We cannot wait for what the future holds for 20/20 GeneSystems and we are excited with our current path forward!  We thank you for your support and for the thousands of followers that haven't yet invested, yes, the train is leaving the station. Don't get left behind!

06.15.21

Last Day To Invest In This Offering!

Welcome to the last day!  As we look towards closing this round, we need your help to get more funding.  We have seen the power of crowdfunding first-hand as a powerful way to shape the future we live in.  If you haven’t invested in 20/20 GeneSystems yet, we urge you to join us on this journey with us! Please share this opportunity to invest in the forefront of cancer diagnostics with your friends and family!  

06.12.21

3 Days Left: The Final Countdown!

Only 3 days left! Did you know that 20/20 GeneSystems has over 5K followers on StartEngine?!  We know you’re watching diligently as our raise continues to grow.  This is your opportunity to become a part-owner of a company that is truly making a difference in the world around us everyday.  This is your chance to make a difference by investing in 20/20 GeneSystems today - Don’t miss out!

06.11.21

Treating Early Stage Lung Cancer - 4 Days Left

The most exciting trend in cancer treatments is undoubtedly immunotherapy, the approach of stimulating the body’s immune system to fight tumors.   For the most part these treatments have been reserved for late stage cancers when survival odds tend to be bleak.   However, last month there was a report of the first immunotherapy drug to significantly reduce the risk of cancer recurrence or death in people with early-stage lung cancer.Atezolizumab reduced by 34% the risk of disease recurrence or death in a certain group of people with stage II to IIIA non-small cell lung cancer.  Lung cancer is the leading cancer killer in the United States, accounting for a quarter of all cancer deaths, the American Lung Association says. Non-small cell lung cancer makes up 4 out of 5 lung cancer cases.

 

Experts suggest that this development will increase demand for tests that can aid in the early detection of lung cancer since the drug represents an opportunity to save the lives of lung cancer patients, if their malignancies are caught in time.

"It is important to emphasize that patients need screening to detect lung cancer early, when it is potentially curable," said Dr. Heather Wakelee, chief of oncology at the Stanford University Medical Center.

 

Fortunately, early detection of lung cancer has been a longstanding focus of 20/20 GeneSystems.   Our first cancer test called “PAULAs test” was focused on non-small cell lung cancer and this test measured many of the same biomarkers in OneTest.   We are now transitioning the lung cancer algorithm developed with PAULAs test into OneTest.


06.10.21

StartEngine Secondary Details - 5 Days Left!!

We’re approaching the final days of being able to invest in this round of fundraising! We intend to quote on StartEngine Secondary - So we figured this would be a perfect time to give some more details on how it works!
StartEngine Secondary is intended to be one of the first public trading marketplaces in the US for companies that have raised capital via Regulation A+ and Regulation Crowdfunding.  Today if you invest in a company on StartEngine, you typically can’t exit your investment until that company experiences a liquidity event, such as being acquired by another business or an IPO.  Those events can take anywhere from 5-10 years to occur, if they occur at all.  
StartEngine hopes to change that with StartEngine Secondary.  The long term plan for StartEngine Secondary is for investors to trade their startup investments on their public marketplace if available.  The main intention is to bring potential liquidity to the private investment marketplace.  
We here at 20/20 GeneSystems are very excited about potentially being one of the first companies to quote on StartEngine Secondary and we cannot wait to see what the next steps are for this new age in finance that is constantly evolving in front of our eyes!
Don’t wait to invest in 20/20 GeneSystems today!

While the company has signed a quotation agreement to trade the securities offered on StartEngine Secondary’s new alternative trading system (the “ATS”), a company which intends to be quoted on the marketplace will be subject to certain requirements which the company may or may not be able to satisfy in a timely manner. Even if a company is qualified to quote its securities on the market, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

06.09.21

Treating Early Stage Lung Cancer - 6 Days Left


The most exciting trend in cancer treatments is undoubtedly immunotherapy, the approach of stimulating the body’s immune system to fight tumors.   For the most part these treatments have been reserved for late stage cancers when survival odds tend to be bleak.   However, last month there was a report of the first immunotherapy drug to significantly reduce the risk of cancer recurrence or death in people with early-stage lung cancer. Atezolizumab reduced by 34% the risk of disease recurrence or death in a certain group of people with stage II to IIIA non-small cell lung cancer.  Lung cancer is the leading cancer killer in the United States, accounting for a quarter of all cancer deaths, the American Lung Association says. Non-small cell lung cancer makes up 4 out of 5 lung cancer cases.

Experts suggest that this development will increase demand for tests that can aid in the early detection of lung cancer since the drug represents an opportunity to save the lives of lung cancer patients, if their malignancies are caught in time.

"It is important to emphasize that patients need screening to detect lung cancer early, when it is potentially curable," said Dr. Heather Wakelee, chief of oncology at the Stanford University Medical Center.

Fortunately, early detection of lung cancer has been a longstanding focus of 20/20 GeneSystems.   Our first cancer test called “PAULAs test” was focused on non-small cell lung cancer and this test measured many of the same biomarkers in OneTest.   We are now transitioning the lung cancer algorithm developed with PAULAs test into OneTest. 

06.08.21

Final 7 Days For This Round Of Fundraising Left!

As we approach our final week of fundraising, we must say, this raise has been an amazing testament to what we do here at 20/20 GeneSystems.  We’d like to take this opportunity to thank the people behind the scenes who consistently push us to make the world a better place.  Our team works tirelessly to work through these important issues - they deserve our recognition and support.  If this sounds like a company you can see yourself identifying with, please invest now as this offer will not last much longer!

06.05.21

OneTest for Cardio Planned

Over the past few weeks 20/20 has taken preliminary steps towards applying our pioneering testing methodology to diseases beyond cancer.  


The unique approach of OneTest for Cancer (which we call “20/20 Hindsight”) is to harvest large quantities of real-world outcome data from previously tested individuals and use it to build machine learning algorithms that help predict likelihood of disease.   Our next target is cardiovascular disease which remains the #1 killer in most of the world.  


Last month we retained two medical specialists as consultants to help us identify data sources that may permit us to build “OneTest for Cardio.”   Neil Kramer, M.D. has practiced cardiology for over four decades  and Michael Rose, M.D. practices internal medicine at Johns Hopkins medical system.  

06.03.21

Most Supplemental Insurance Plans Pay for OneTest


Over 40% of large employers in the U.S., public and private sector, offer supplemental insurance (a/k/a "voluntary benefits") to their employees. Many of these plans, from carriers such as Aflac, MetLife, and others, include a wellness or screening benefit that pays policy holders at least $50 once per year for designated screening tests. The biomarkers measured with OneTest (PSA, CEA, etc.) qualify for a screening benefit with most of these plans. An example of one such benefit list may be viewed here.

 

A leading national voluntary benefits carrier is now conducting a pilot in a Maryland county to assess the value of offering OneTest to its beneficiaries and customer leads.  We are hoping the assessments leads to a relationship with the carrier, which could potentially expand exposure to our products and cover the bulk of future customers testing costs.  




06.02.21

20/20’s Shares are Expected to Quote on StartEngine Secondary

Since the implementation of the JOBS Act of 2012 Americans at nearly all economic levels have been free to buy stock in companies before they go public.  This was a revolutionary change in that since the 1930’s only wealthy individuals were free to invest in these companies (with some limited exceptions.)   However for equity crowdfunding to be sustainable it is important to expand opportunities not only to buying stock but for selling as well.

We are therefore pleased to announce our intention to become one of the first crowdfunded companies to quote our shares on StartEngine Secondary, a new “alternative trading system” or “ATS” established specifically for companies like 20/20 that have succeeded under Regulation A+.  Our hope is to provide liquidity to our shareholders through this new endeavor for 20/20 GeneSystems.

While the company has signed a quotation agreement to trade the securities offered on StartEngine Secondary’s new alternative trading system (the “ATS”), a company which intends to be quoted on the marketplace will be subject to certain requirements which the company may or may not be able to satisfy in a timely manner. Even if a company is qualified to quote its securities on the market, there is no guarantee an active trading market for the securities will ever develop, or if developed, be maintained. You should assume that you may not be able to liquidate your investment for some time or be able to pledge these shares as collateral.

REWARDS

Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into 20/20 GeneSystems, Inc..

JOIN THE DISCUSSION

0/2500

RM
Raymond Marine

a month ago

20/20 You are starting to turn into another one of those SCAM companies. I already have a lot of them on StartEngine. When Will You Update Investors?

0

0

gW
gary Waller

7 months ago

How do I sale my shares

0

0

DL
Duc Le

8 months ago

I invested $2500 since 2021 but haven’t yet received the multi-cancer or lung test. Has anyone received it?

1

0













JC
Joseph Couch

10 months ago

This company has not responded to questions on both of their campaign's. I suggest not investing in a company that does this.

0

0

DM
David Mboh

a year ago

Hello, I think you can reach the company directly using this contact: admin@2020gene.com I believe they'd sent out a google form for those that wanted to convert their shares from preferred to common so that they become tradable on StartEngine Secondary Market. I did fill the form and my shares appeared automatically on the first day of trading. Y'all probably missed the email, didn't receive or ignored it. With regards to trading your shares for those who had converted their shares to common, sorry to say that is impossible at the moment because apparently, StartEngine is currently migrating to a better platform or making some updates on their platform. I guess a more reason why some of your investments don't show a completion; funds invested for example. I suggest you contact StartEngine directly using contact@startengine.com. They're always reply promptly. Just an investor like you. Hope that helps.

3

1













RQ
Robert Quail

26 INVESTMENTS

a year ago

sorry for the double post. first verification indicated a failure.

0

0

RQ
Robert Quail

26 INVESTMENTS

a year ago

On Wed, Feb 2, 2022 at 8:28 PM <quailrt@att.net> wrote: Client service SIXTH request I received a 1099-B for a sale of 51 shares of TWTG from Prime Trust showing a sale proceeds of $4205.49 and a cost of $2156.65, (I wish), sold on 12/27/2021. My records, based on what little I get from Start Engine notes a sale of 100shs. on 12/28/21, 2:59pm @ $3.20/sh. Payer's TIN 81-2236823 (?). I tried to contact PT, voice message only, did not help. I need this corrected or send me the money I was supposed have made on the trade. Start Engine needs to improve their account statements. Tell your CEO/founder to use the site; if they thinks this is the best SE can do, they should resign. We a professional spread sheet. I have written several times on the need for an improvement in investor information; one non-answer, answer was received. Last email was not answered. I need this fixed. This an IRS matter. A prompt response would be greatly appreciated. A call back number would be be more helpful to resolve this issue as it pertains to all investments. I'm now in the of filing a complaint with FINRA. I have not hit send yet, but will at 7pm tonight unless I get a solution to the error. Please don't tell me to file a form 8949, because Start Engine's statement are of such poor quality the IRS may not accept the data. The system is quite convoluted as compared to a professionally run brokerage firm. I have always considered obfuscation as a lawyer's twist of the written language to justify a means to interpret a process to the clients advantage. I hope this is not the case with the organizations involved in what should been a very simple accounting function. Both 2020 and SE review and improve their client communication procedure. No one wishes to be ignored where money is involved. R.T.Quail NOTE; Prime has a very poor one star rating form the BBB.I suggest ST advise clients not to use this Co. RTQ

0

1

gW
gary Waller

a year ago

i have been trying to sale my shares/trade and it wont let me I filled out all the forms for trading and have been trying to get someone to help but no response. not sure where my money is?? no one will tell me. something is wrong with this company

0

1

gW
gary Waller

a year ago

how do I sale my shares

0

1

DP
Deepak Patnaik

27 INVESTMENTS

a year ago

Hi, how to transfer my investment to secondary market?

0

0

HOW INVESTING WORKS

Cancel anytime before 48 hours before a rolling close or the offering end date.

WHY STARTENGINE?

REWARDS

We want you to succeed and get the most out of your money by offering rewards and memberships!

SECURE

Your info is your info. We take pride in keeping it that way!

DIVERSE INVESTMENTS

Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.

PREVIOUSLY CROWDFUNDED
$7,563,950.51
RAISED
$1,510,607.20
INVESTORS
1,352
MIN INVEST
$501.60
VALUATION
$57.38M

@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team

Careers

Blog

Important Message

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE ISSUER AND THE TERMS OF THE OFFERING, INCLUDING THE MERITS AND RISKS INVOLVED. INVESTMENTS ON STARTENGINE ARE SPECULATIVE, ILLIQUID, AND INVOLVE A HIGH DEGREE OF RISK, INCLUDING THE POSSIBLE LOSS OF YOUR ENTIRE INVESTMENT.


www.StartEngine.com is a website owned and operated by StartEngine Crowdfunding, Inc. (“StartEngine”), which is neither a registered broker-dealer, investment advisor nor funding portal.


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.


Investment opportunities posted and accessible through the site are of three types:


1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.


Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.


By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.


Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.


California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to contact@startengine.com.


StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.